romosozumab + denosumab

Romosozumab + denosumab is a combination therapy consisting of two monoclonal antibodies used in the management of severe osteoporosis, particularly in postmenopausal women at high risk for fractures. Romosozumab is a humanized IgG2 monoclonal antibody that targets and inhibits sclerostin, a protein secreted by osteocytes that suppresses bone formation via inhibition of the Wnt signaling pathway. By blocking sclerostin, romosozumab promotes bone formation and also reduces bone resorption through downstream effects on RANKL production[6][8]. Denosumab is a fully human monoclonal antibody that binds to receptor activator of nuclear factor kappa-B ligand (RANKL), preventing its interaction with the RANK receptor on osteoclasts and their precursors, thereby inhibiting osteoclast-mediated bone resorption[7]. The combination has been studied primarily in patients who have responded poorly to long-term denosumab monotherapy; adding romosozumab can further increase lumbar spine bone mineral density (BMD) and enhance markers of bone formation compared to either agent alone[1][3][5]. This dual approach leverages both anabolic (romosozumab) and antiresorptive (denosumab) mechanisms for optimal skeletal benefit.